FBL10 CRISPR/Cas9 KO Plasmid (h): sc-403232
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- FBL10 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the FBL10 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: FBL10 Antibody (5G1): sc-293279
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
FBL10 CRISPR/Cas9 KO Plasmid (h) | sc-403232 | 20 µg | $397.00 |
Overview
KDM2B encodes the human protein FBL10, a JmjC-domain histone lysine demethylase that recognizes CpG-rich DNA via its CxxC zinc finger and modulates chromatin accessibility. FBL10 participates in Polycomb-associated transcriptional repression and helps coordinate epigenetic programs controlling cell-cycle progression, lineage commitment, and maintenance of cellular identity. Through regulation of histone methylation states and promoter/enhancer activity, KDM2B influences pathways governing proliferation and differentiation. Dysregulated KDM2B activity and altered chromatin targeting have been linked to oncogenic transcriptional states and aberrant stem-like phenotypes in diverse cancer and hematopoietic contexts, making it a useful locus for mechanistic studies of epigenetic control.
FBL10 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the KDM2B gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the KDM2B together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the KDM2B open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish FBL10 protein expression.
This CRISPR knockout system enables efficient generation of KDM2B-deficient cell models for investigation of FBL10 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting KDM2B exon(s) critical for FBL10 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple KDM2B genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by FBL10 CRISPR/Cas9 KO Plasmid (h) and FBL10 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the KDM2B locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by FBL10 HDR Plasmid (h) and FBL10 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by KDM2B homology arms to support homology-directed repair at defined KDM2B target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.